Noncompetitive inhibitor of 3-phosphoglycerate dehydrogenase (PHGDH; IC50 value 33 µM) with selective toxicity towards cancer cell lines with high serine biosynthetic activity. CBR-5884 shows no inhibitory effect on two other NAD+-dependent dehydrogenases, lactate dehydrogenase (LDH) and MDH1A. A useful tool to study the biology of de novo serine synthesis enabling preclinical evaluation of PHGDH as a target in cancer.

KEYWORDS: CBR 5884 | supplier | PHGDH inhibitor | CBR5884 | CAS [681159-27-3] | 3-phosphoglycerate | PHGDH | dehydrogenase | breast | cancer | serine biosynthesis | NAD+ dependent